JP2018532693A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532693A5
JP2018532693A5 JP2018506110A JP2018506110A JP2018532693A5 JP 2018532693 A5 JP2018532693 A5 JP 2018532693A5 JP 2018506110 A JP2018506110 A JP 2018506110A JP 2018506110 A JP2018506110 A JP 2018506110A JP 2018532693 A5 JP2018532693 A5 JP 2018532693A5
Authority
JP
Japan
Prior art keywords
antibody
seq
fragment
insulin
hypoglycemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045917 external-priority patent/WO2017024285A2/en
Publication of JP2018532693A publication Critical patent/JP2018532693A/ja
Publication of JP2018532693A5 publication Critical patent/JP2018532693A5/ja
Pending legal-status Critical Current

Links

JP2018506110A 2015-08-06 2016-08-05 インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用 Pending JP2018532693A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562202143P 2015-08-06 2015-08-06
US62/202,143 2015-08-06
US201662280675P 2016-01-19 2016-01-19
US62/280,675 2016-01-19
PCT/US2016/045917 WO2017024285A2 (en) 2015-08-06 2016-08-05 Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

Publications (2)

Publication Number Publication Date
JP2018532693A JP2018532693A (ja) 2018-11-08
JP2018532693A5 true JP2018532693A5 (https=) 2019-09-12

Family

ID=56684310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506110A Pending JP2018532693A (ja) 2015-08-06 2016-08-05 インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用

Country Status (8)

Country Link
US (2) US10253101B2 (https=)
EP (1) EP3331562A2 (https=)
JP (1) JP2018532693A (https=)
CN (1) CN108136006A (https=)
AU (1) AU2016304588A1 (https=)
CA (1) CA2994841A1 (https=)
HK (1) HK1255271A1 (https=)
WO (1) WO2017024285A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10711067B2 (en) * 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
BR112020014719A2 (pt) * 2018-01-23 2020-12-08 Xeris Pharmaceuticals, Inc. Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose
CA3255928A1 (en) * 2022-05-20 2023-11-23 Xoma (Us) Llc Formulations for Insulin Receptor Antibodies and Their Uses
AU2023308137A1 (en) * 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.
WO2025043134A1 (en) 2023-08-24 2025-02-27 Rezolute, Inc. High concentration formulations for anti-insulin receptor antibody and uses thereof
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US5463768A (en) 1994-03-17 1995-10-31 General Electric Company Method and system for analyzing error logs for diagnostics
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP2036574A4 (en) 2006-06-06 2009-07-01 Oleg Iliich Epshtein MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
EP4159114B1 (en) 2007-10-09 2024-04-10 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
US9102711B2 (en) 2007-12-31 2015-08-11 Xoma Technology Ltd. Methods and materials for targeted mutagenesis
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery

Similar Documents

Publication Publication Date Title
JP2018532693A5 (https=)
AU2017246460A1 (en) Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
JP2018535948A5 (https=)
CN1829532A (zh) 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
JP2017537105A5 (https=)
JP2016528247A5 (https=)
CN113134095A (zh) 治疗骨髓瘤
JP2015525798A5 (https=)
JP2020535149A5 (https=)
JP2005506331A5 (https=)
ES2965454T3 (es) Protocolo mejorado para el tratamiento de la nefritis lúpica
JP2020504717A5 (https=)
JP2018512402A5 (https=)
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
CN113194821A (zh) 逆转替卡格雷活性的方法
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
EP2167038B1 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
JP2003528890A (ja) 胃腸管の炎症性疾患の処置におけるcd25結合分子の使用
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
ES2935265T3 (es) Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control
Pharand et al. Potential anaphylactic shock with abciximab readministration
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
JPWO2023133388A5 (https=)
JPWO2022075476A5 (https=)
KR20260058844A (ko) 전립선암 치료를 위한 조합 요법